Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

This publication has 18 references indexed in Scilit:

• A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
  New England Journal of Medicine, 2001
• Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors
  American Heart Journal, 2000
• Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry
  European Heart Journal, 1999
• Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure
  Journal of Cardiac Failure, 1999
• Heart Failure Treatment With Angiotensin-Converting Enzyme Inhibitors in Hospitalized Medicare Patients in 10 Large States
  Archives of internal medicine (1960), 1997
• Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
  Journal of Clinical Investigation, 1997
• Role of Bradykinin in Mediating Vascular Effects of Angiotensin-Converting Enzyme Inhibitors in Humans
  Circulation, 1997
• Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure
  JAMA, 1995
• Proposed Update of Angiotensin Receptor Nomenclature
  Hypertension, 1995
• Evidence of inadequate investigation and treatment of patients with heart failure.
  Heart, 1994